JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis-Reference-Cited by-同舟云学术

JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis

Published:2018-03-22 Issue:8 Volume:19 Page:664-668
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Choi Michael Y.¹,Kato Shumei¹,Wang Huan-You²,Lin Jonathan H.²,Lanman Richard B.³,Kurzrock Razelle¹

Affiliation:

1. Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California San Diego Moores Cancer Center, La Jolla, CA, USA

2. Department of Pathology, University of California San Diego, La Jolla, CA, USA

3. Guardant Health, Redwood City, CA, USA

Funder

National Cancer Institute

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384047.2018.1450120

Reference36 articles.

1. Erdheim-Chester Disease Harboring the BRAF V600E Mutation

2. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses

4. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JAK: Not Just Another Kinase;Molecular Cancer Therapeutics;2022-10-17

2. Discovery, Significance, and Utility of JAK2 Mutation in Squamous Cell Carcinoma of the Lung;Cureus;2022-06-13

3. Erdheim–Chester disease: a case treated with IFN-α monitored using plasma and urine cell-free DNA;Immunotherapy;2020-04